By Anthony O. Goriainoff

 

AstraZeneca PLC said Thursday that Fasenra met both co-primary endpoints in the OSTRO Phase 3 trial for patients with chronic rhinosinusitis with nasal polyps.

Fasenra--a treatment for severe eosinophilic asthma--showed a significant improvement in the size of nasal polyps and in nasal blockage in patients, the company said.

The FTSE 100-listed drug maker said Fasenra demonstrated a statistically significant improvement in the endoscopic total nasal polyp score and the nasal blockage score compared with placebo in patients with severe bilateral nasal polyposis who were still symptomatic despite continued treatment with standard of care. Standard of care consists of intranasal corticosteroids and prior surgery and/or use of systemic corticosteroids, the company said.

Eosinophilic asthma is a type of severe asthma usually marked by high levels of white blood cells.

"Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma in the U.S., EU, Japan and other countries, and is approved for self-administration in the U.S., EU and other countries," the company said.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

September 10, 2020 02:44 ET (06:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
FTSE 100
Index Chart
From Dec 2020 to Jan 2021 Click Here for more FTSE 100 Charts.
FTSE 100
Index Chart
From Jan 2020 to Jan 2021 Click Here for more FTSE 100 Charts.